Daniel Barber
Principal executive officer pay for Daniel Barber, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Aquestive Therapeutics, Inc. (AQST) FY2022–FY2024
Aligned: paid up as stock roseCAP $704,731→$5,227,461 while $100 invested went $23.19→$91.52
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $1.3M | $704,731 |
| FY2023 | $2.5M | $3.3M |
| FY2024 | $4.2M | $5.2M |
The company's "$100 invested" index ran $23.19 at FY2022 → $91.52 by FY2024 — an annualized return of 98.7%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 98.7%/yr at AQST ( FY2022–FY2024). See the CEO track-record ranking for context.